Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

37.51
-0.2300-0.61%
Pre-market: 38.000.4900+1.31%09:04 EDT
Volume:1.32M
Turnover:50.29M
Market Cap:2.62B
PE:-12.53
High:39.03
Open:37.60
Low:37.00
Close:37.74
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.74
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.51
PE(LYR):-10.76

Loading ...

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

GlobeNewswire
·
May 08

Pharvaris CMO Lu Peng disposes of shares worth $427,111.81

Reuters
·
May 06

Pharvaris Chief Early Development Anne Lesage disposes of shares worth $1.32 million

Reuters
·
May 02

Pharvaris (PHVS) Valuation Check After Conference Data Support For Deucrictibant Combination Regimen

Simply Wall St.
·
Apr 28

Top Pharvaris Executive Executes Notable Insider Stock Sale

TIPRANKS
·
Apr 25

Pharvaris director Johannes Schikan disposes 7,100 shares for $213,678.70

Reuters
·
Apr 25

Pharvaris Chief Early Development Anne Lesage disposes of USD 225,511 common shares

Reuters
·
Apr 25

Pharvaris Chief Medical Officer Lu Peng disposes of common shares worth $213,411

Reuters
·
Apr 24

Is Evidence Backing Dual Deucrictibant Use Altering The Investment Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 21

Pharvaris presents data from deucrictibant IR capsule and XR tablet study

TIPRANKS
·
Apr 20

Pharvaris data support combining deucrictibant XR prophylaxis with IR dosing for breakthrough attacks

Reuters
·
Apr 20

Pharvaris price target raised to $52 from $48 at JonesResearch

TIPRANKS
·
Apr 16

Pharvaris Initiated at Outperform by Wolfe Research

Dow Jones
·
Apr 10

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

TIPRANKS
·
Apr 08

Pharvaris Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 07

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

MT Newswires Live
·
Apr 06

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Benzinga_recent_news
·
Apr 06

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 06

RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 05